
USAupdated 53m ago2 min read
Archive photo · 28 July 2007White House Drops Heidi Overton’s FDA Commissioner Nomination After GOP Senators Raise Vote Concerns
7 Western MainstreamPhoto: Diego Delso, CC BY-SA 3.0 · Cropped for layout
This article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
White House withdrew Heidi Overton's FDA nomination amid lack of Senate Republican support. Nomination faced concerns over abortion stance and vaccines, jeopardizing confirmation vote.
Save coverage image
Overton Nomination Pulled
The White House dropped Dr. Heidi Overton’s nomination to lead the Food and Drug Administration after GOP senators signaled she lacked the votes needed for Senate confirmation.
An official confirmed the White House had dropped the nomination, and Overton’s nomination faced an uphill battle with GOP senators over her stances on abortion, vaccines and vaping.
AP said the White House pulled the nomination because “growing indications she didn’t have the votes needed to win Senate confirmation,” and AP described Overton as a physician and White House domestic policy adviser.
AP also said the FDA has been without a permanent leader for nearly seven months, with acting FDA Commissioner Kyle Diamantas temporarily leading the agency.
NBC News added that the decision came a day before the Senate Health Committee was scheduled to vote on whether to advance her nomination to the full Senate for confirmation.

Cassidy, Abortion Commitments
Sen. Bill Cassidy said he believed Overton would have had the votes to pass out of committee and pass the full Senate, and he argued the sticking point involved requests from anti-abortion Republicans for final assurances from the administration.
Cassidy told reporters, “The Administration withdrew Dr. Overton rather than make such commitments,” and ABC News said Cassidy contended confirmation of a new FDA commissioner would now fall to Senate Democrats.
Cassidy criticized the White House for pulling Overton’s nomination, writing on X, “Tonight, the White House abandoned a viable confirmation path for Dr. Overton.”
AP said the FDA is conducting a safety review of the abortion pill mifepristone at the request of Trump, and AP said the FDA has promised a report on its safety findings by March.
The Guardian quoted Mini Timmaraju saying, “Heidi Overton posed a serious threat to the future of medication abortion access,” after the White House withdrew the nomination.
What Happens Next
AP said Overton would have needed the votes of all 12 Republicans on the Senate Health, Education, Labor and Pensions Committee, with Democrats holding 11 seats, and AP said without support of the committee she faced little chance of winning a full Senate vote. Democrats take control of the Senate in early January, and Overton’s chances of being confirmed under a Democratic-controlled Senate would be slim if she were not confirmed in this Congress. ABC News said it was unclear when the president will nominate a new choice for FDA commissioner and if the Senate will work to confirm the new nominee during a lame duck session.
AP said the FDA is currently being led on an acting basis by Kyle Diamantas, and AP said acting officials are limited to about seven months leading a federal agency. CBS News said the White House had begun looking for a new candidate, including candidates who could serve in an acting capacity and thus forgo Senate confirmation.
